2003/11/11 by Chelsea S. Kidwell, Steven Warach · 2 citations
Medicine · #Acute Ischemic Stroke Management #Intracerebral and Subarachnoid Hemorrhage Research #Neurological and metabolic disorders #Medicine #Neuroimaging #Stroke (engine) #Ischemia #Disease #Clinical trial #Vascular disease #Brain ischemia #Intensive care medicine #Ischemic stroke #Central nervous system disease #Radiological weapon #Cardiology #Internal medicine #Surgery #Psychiatry
paper · doi:10.1161/01.str.0000098902.69855.a9
openalex publication_date 2003/11/11 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/15
BACKGROUND: Existing diagnostic classification systems for cerebrovascular disease are based primarily on clinical impression of temporal features, clinical syndrome, inferred localization, or ischemic mechanism. Diagnostic certainty of the ischemic pathology based on supportive or refuting laboratory or radiological evidence has been of secondary importance. SUMMARY OF COMMENT: Acute ischemic cerebrovascular syndrome (AICS) describes a spectrum of clinical presentations that share a similar underlying pathophysiology: cerebral ischemia. Diagnostic criteria for AICS incorporate prior classification systems and currently available information provided by neuroimaging and laboratory data to define 4 categories ranging from "definite AICS" to "not AICS," which define the degree of diagnostic certainty. CONCLUSIONS: Clinical trials testing new treatments for acute ischemic stroke or secondary stroke prevention should limit enrollment to patients with "definite" AICS whenever feasible.